CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $32.63M, above the global median of $18.73M
- PositionReturn on equity is 16.8%, higher than 95% of its Medical Devices peers (median 2.5%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.72%Above 5Y avg (2.08%)
Annual Rate
CNY 0.31Paid annual
Payout Ratio
51.1%Sustainable
Payback Period
37.5 yr
Last Ex-Dividend
Apr 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.62BCNY987.80M · vs all stocks (USD)
Trailing P/E
18.72xvs Medical Devices peers
Revenue (TTM)
2.11BCNY314.64M · vs all stocks (USD)
Profit Margin
16.74%vs Medical Devices peers
Beta
0.5120xvs all stocks
52-Week Change
-4.99%vs all stocks
Market Capitalization
6.62BCNY987.80M · vs all stocks (USD)
Enterprise Value
5.44BCNY811.68M · vs all stocks (USD)
Trailing P/E
18.72xvs Medical Devices peers
Forward P/E
26.56xvs Medical Devices peers
Price to Sales (TTM)
3.14xvs Medical Devices peers
Price to Book (MRQ)
2.99xvs Medical Devices peers
Enterprise to Revenue
2.58xvs Medical Devices peers
Enterprise to EBITDA
12.94xvs Medical Devices peers
Gross Margin
60.75%vs Medical Devices peers
Profit Margin
16.74%vs Medical Devices peers
Operating Margin
20.92%vs Medical Devices peers
Return on Assets (TTM)
9.60%vs Medical Devices peers
Return on Equity (TTM)
16.79%vs Medical Devices peers
Revenue (TTM)
2.11BCNY314.64M · vs all stocks (USD)
Revenue per Share (TTM)
3.64CNYUpdated Sep 20, 2026Quarterly Revenue Growth
2.80%vs Medical Devices peers
Gross Profit (TTM)
1.24BCNY184.50M · vs all stocks (USD)
EBITDA (TTM)
374.26MCNY55.85M · vs all stocks (USD)
Net Income (TTM)
353.03MCNY52.68M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.30%vs Medical Devices peers
Operating Cash Flow (TTM)
417.27MCNY62.26M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
218.68MCNY32.63M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3110CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
2.72%vs all stocks
5-Year Average Dividend Yield
2.08%vs all stocks
Payout Ratio
51.07%vs Medical Devices peers
Minority Interest (Equity)
1.23MCNYFY2025 · Dec 31, 2025Revenue
2.00BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
832.54MCNYFY2025 · Dec 31, 2025Gross Profit
1.17BCNYFY2025 · Dec 31, 2025Operating Income
317.14MCNY47.32M · vs all stocks (USD)
Pre-tax Income
316.17MCNYFY2025 · Dec 31, 2025Income Tax Expense
8.19MCNYFY2025 · Dec 31, 2025Net Income
307.98MCNYFY2025 · Dec 31, 2025EBIT
317.60MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
384.51MCNYFY2025 · Dec 31, 2025Research & Development
301.82MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
186.78MCNYFY2025 · Dec 31, 2025Other Operating Expenses
20.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.42MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5273CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5273CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
579.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
579.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
307.98MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.34MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
272.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
187.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.26BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
307.98MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.80MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-48.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.76MCNYFY2025 · Dec 31, 2025Capital Expenditures
-84.57MCNYFY2025 · Dec 31, 2025Sale of Investments
5.07MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-79.50MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-120.43MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.14MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-132.56MCNYFY2025 · Dec 31, 2025Shares Outstanding
579.66MSharesUpdated Sep 20, 2026Float Shares
253.97MSharesUpdated Sep 20, 2026% Held by Insiders
58.04%vs all stocks
% Held by Institutions
3.06%vs all stocks
Total Cash (MRQ)
1.21BCNY181.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.09CNYUpdated Sep 20, 2026Total Debt (MRQ)
29.64MCNY4.42M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0134xvs Medical Devices peers
Current Ratio (MRQ)
5.35xvs Medical Devices peers
Book Value per Share (MRQ)
3.82CNYUpdated Sep 20, 2026Total Assets
2.64BCNY394.50M · vs all stocks (USD)
Total Current Assets
1.88BCNYFY2025 · Dec 31, 2025Total Liabilities
449.82MCNYFY2025 · Dec 31, 2025Total Non-current Assets
761.19MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
46.77MCNYFY2025 · Dec 31, 2025Total Current Liabilities
403.05MCNYFY2025 · Dec 31, 2025Cash
1.27BCNYFY2025 · Dec 31, 2025Cash Equivalents
12.81MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.29BCNYFY2025 · Dec 31, 2025Accounts Receivable
195.23MCNYFY2025 · Dec 31, 2025Inventory
340.40MCNYFY2025 · Dec 31, 2025Accounts Payable
197.38MCNYFY2025 · Dec 31, 2025Short-term Debt
10.30MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.38MCNYFY2025 · Dec 31, 2025Long-term Debt
20.22MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
13.39MCNYFY2025 · Dec 31, 2025Common Stock (Book)
579.66MCNYFY2025 · Dec 31, 2025Retained Earnings
1.06BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.19BCNY327.38M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
10.91CNYUpdated Sep 20, 202652-Week High
16.80CNYUpdated Sep 20, 202652-Week Change
-4.99%vs all stocks
Beta
0.5120xvs all stocks
50-Day MA
11.78CNYUpdated Sep 20, 2026200-Day MA
13.44CNYUpdated Sep 20, 2026Avg 10-Day Volume
4.33MSharesUpdated Sep 20, 2026Avg 30-Day Volume
5.16MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.6100CNYUpdated Sep 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 16.8%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 0.17Industry median: 0.03Industry P95: 0.17Peers compared: 102
Financial Health
Altman Z-Score 11.21: safe zoneNotable
Altman Z-Score: 11.21
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $32.63M, above the global median of $18.73MNotable
Levered free cash flow (USD): 32,631,014.172Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
T.S. Lines Ltd
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityMinimal Tax and Interest DragIndustry-Benchmarked Return on Capital Elevated
Feng Hsin Steel Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked Return on Capital Elevated
Saudi Aramco Base Oil Company
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityMinimal Tax and Interest Drag